Success of Daiichi Sankyo’s New Midterm Plan to Hinge on Edoxaban; 120 Billion Yen Sales Target Set for FY2020

Daiichi Sankyo announced its fourth midterm business plan for FY2016-FY2020 on March 31. The company has completely revised its third midterm plan for FY2013-FY2017 due to its sale of the major generic drug maker Ranbaxy Laboratories of India. With the...read more